Publications

Detailed Information

Prognostic Implications of Ezrin Expression in Human Hepatocellular Carcinoma

DC Field Value Language
dc.contributor.authorKang, Yun Kyung-
dc.contributor.authorHong, Seong Woo-
dc.contributor.authorLee, Hyucksang-
dc.contributor.authorKim, Woo Ho-
dc.date.accessioned2012-06-01T07:55:26Z-
dc.date.available2012-06-01T07:55:26Z-
dc.date.issued2010-09-
dc.identifier.citationMOLECULAR CARCINOGENESIS; Vol.49 9; 798-804ko_KR
dc.identifier.issn0899-1987-
dc.identifier.urihttps://hdl.handle.net/10371/76723-
dc.description.abstractEzrin is known to regulate cellular survival, adhesion, migration, and invasion and has been identified as one of the key components of tumor progression and metastasis. The authors investigated ezrin expression in human hepatocellular carcinoma (HCC) and sought to determine its relation with clinicopathologic parameters, patients` outcome, and interacting molecular markers. Ezrin expression was assessed by immunohistochemical staining in 100 surgically resected HCCs using the tissue microarray method. A total of 28 HCCs showed high ezrin immunoreactivity, mainly in cytoplasm. Ezrin expression exhibited a positive correlation with c-Met expression (P = 0.001), but showed no correlation with the expression of CD44s or E-cadherin. HCCs expressing high level of ezrin were significantly associated with advanced TNM stage, poor Edmondson`s histological grade, macroscopic portal vein invasion, tumor recurrence, and extrahepatic recurrence (P < 0.05). Univariate analysis showed that HCCs with high ezrin immunoreactivity were strongly associated with unfavorable overall and disease-free survivals than HCCs with low or negative for ezrin immunoreactivity (P = 0.0001 and 0.0011, respectively). Furthermore, multivariate analysis demonstrated that a high level of ezrin expression was independently associated with poor overall survival (hazard ratio, 1.905; P = 0.011). The results suggest that ezrin expression could be a potential predictive marker of progression, metastasis, and prognosis in HCC. (C) 2010 Wiley-Liss, Inc.ko_KR
dc.language.isoenko_KR
dc.publisherWILEY-LISSko_KR
dc.subjecthepatocellular carcinomako_KR
dc.subjectezrinko_KR
dc.subjectimmunohistochemistryko_KR
dc.subjectprotooncogene protein c-Metko_KR
dc.subjectsurvival analysisko_KR
dc.subjecttissue array analysisko_KR
dc.titlePrognostic Implications of Ezrin Expression in Human Hepatocellular Carcinomako_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor강윤경-
dc.contributor.AlternativeAuthor홍성우-
dc.contributor.AlternativeAuthor이혁상-
dc.contributor.AlternativeAuthor김우호-
dc.identifier.doi10.1002/mc.20653-
dc.citation.journaltitleMOLECULAR CARCINOGENESIS-
dc.description.citedreferenceElzagheid A, 2008, HUM PATHOL, V39, P1737, DOI 10.1016/j.humpath.2008.04.020-
dc.description.citedreferenceOkamura D, 2008, MODERN PATHOL, V21, P847, DOI 10.1038/modpathol.2008.59-
dc.description.citedreferenceBal N, 2007, WORLD J GASTROENTERO, V13, P3726-
dc.description.citedreferenceBruce B, 2007, CLIN EXP METASTAS, V24, P69, DOI 10.1007/s10585-006-9050-x-
dc.description.citedreferenceZhang Y, 2006, J CANCER RES CLIN, V132, P685, DOI 10.1007/s00432-006-0117-5-
dc.description.citedreferenceMadan R, 2006, HEAD NECK-J SCI SPEC, V28, P1018, DOI 10.1002/hed.20435-
dc.description.citedreferenceLee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377-
dc.description.citedreferenceYeh TS, 2005, ARCH SURG-CHICAGO, V140, P1184-
dc.description.citedreferenceWeng WH, 2005, CLIN CANCER RES, V11, P6198, DOI 10.1158/1078-0432.CCR-05-0548-
dc.description.citedreferenceHustinx SR, 2005, CANCER BIOL THER, V4, P596-
dc.description.citedreferenceELLIOTT BE, 2005, BREAST CANCER RES, V7, P365-
dc.description.citedreferenceHunter KW, 2004, TRENDS MOL MED, V10, P201, DOI 10.1016/j.molmed.2004.03.001-
dc.description.citedreferenceKhanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982-
dc.description.citedreferenceMartin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5-
dc.description.citedreferenceBretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882-
dc.description.citedreference*AM JOINT COMM CAN, 2002, AJCC CANC STAG MAN-
dc.description.citedreference*MIN HLTH WELF HEA, 2002, ANN REP KOR CENTR CA, P12-
dc.description.citedreferenceLara-Pezzi E, 2001, HEPATOLOGY, V33, P1270-
dc.description.citedreferenceMatsumura T, 2001, CLIN CANCER RES, V7, P594-
dc.description.citedreferenceWielenga VJM, 2000, AM J PATHOL, V157, P1563-
dc.description.citedreferenceGautreau A, 1999, P NATL ACAD SCI USA, V96, P7300-
dc.description.citedreferenceAkisawa N, 1999, BIOCHEM BIOPH RES CO, V258, P395-
dc.description.citedreferenceEl-Serag HB, 1999, NEW ENGL J MED, V340, P745-
dc.description.citedreferenceCrepaldi T, 1997, J CELL BIOL, V138, P423-
dc.description.citedreferenceKanai Y, 1997, INT J CANCER, V71, P355-
dc.description.citedreferenceUeki T, 1997, HEPATOLOGY, V25, P862-
dc.description.citedreferenceMathew J, 1996, J PATHOL, V179, P74-
dc.description.tc8-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share